Updated January 14th, 2019, by Nate Parsh
Abbott Laboratories is a very well-known dividend growth stock, and for good reason. The company is a member of the exclusive Dividend Aristocrats, a group of elite dividend stocks with 25+ years of consecutive dividend increases.
Abbott is diversified across multiple areas of health care, each of which has positive growth potential for the long-term. This has fueled Abbott’s impressive history, and will continue to do so in the years ahead. This article will discuss the investment prospects of Abbott Laboratories in detail. Before reading this article, you may want to review Abbott’s fundamentals, which are charted below:
Abbott Laboratories is a diversified healthcare corporation with a market capitalization of $119.96 billion. The company was founded in 1888 and is headquartered in Lake Bluff, Illinois.
The company operates in four main segments:
- Nutritional Products
- Branded Generic Pharmaceuticals
- Medical Devices
The company’s Nutrition Products segment is characterized by market leadership. It is the #1 pediatric nutrition provider in the United States and some other geographies. Moreover, the segment’s performance has improved considerably in recent years as operating margin has improved in each and every year since 2011.
Source: Investor Presentation, page 3
The company’s Branded Generic Pharmaceuticals segment is focused on emerging markets, with an emphasis on BRIC countries (Brazil, Russia, India, and China).
The company’s Diagnostics segment is geographically more diverse than the Branded Generic Pharmaceuticals segment. About 30% of the segment’s revenue is generated in the United States while 30% is generated in non-US developed markets and 40% is generated in emerging markets. Similar to the Nutrition segment, the Diagnostics segment has seen significant operating margin improvements over the last several years.
Abbott Laboratories’ last segment is the Medical Devices unit. This segment was significantly bolstered in recent times by the St. Jude Medical acquisition, which helped the segment to grow sales by nearly 43% in the most recent quarter. The company’s high-quality product portfolio and the acquisition of St. Jude should fuel strong growth for the next several years.
Over time, Abbott Laboratories has shown the capability to reliably grow its adjusted earnings-per-share. Abbott Laboratories spun-off AbbVie (ABBV) in 2013, and both businesses have performed well since the spin-off. If an investor had held onto their shares of both companies, their per-share earnings would total $8.01 in 2017. This is up significantly from the $4.99 (growth of 8.4% per year) of adjusted earnings-per-share reported by the combined company in 2012.
Looking ahead, Abbott Laboratories has two major growth prospects that will help its business to become increasingly more profitable over the years to come.
The first is the aging population, both domestically and within the United States. In 2017, the percent of the global population that exceeded age 65 was 8.7%. This proportion is expected to reach 16.7% in 2050.
Source: Investor Presentation, page 5
The second broad tailwind that will benefit Abbott Laboratories is the company’s focus on the emerging markets. This is particularly true for its Branded Generic Pharmaceuticals segment.
Many of the countries that this segment is focused on spend a very small proportion of their overall GDP on healthcare, a rate that is expected to increase in the future.
The aging domestic population combined with the rather low focus on healthcare spending in emerging market countries should leave Abbott Laboratories plenty of room to grow for the foreseeable future.
Competitive Advantages & Recession Performance
Abbott Laboratories’ competitive advantage is two-fold. The first component is its remarkable brand recognition among its consumer medical products, particularly in its Nutrition segment. Led by noteworthy products like the Ensure meal replacement supplement, Abbott Laboratories brands allows its sales to stand strong through even the worst economic recessions.
The second component of Abbott’s competitive advantage is its focus on research and development. The company’s R&D expense over the last several years is shown below:
- 2014 research & development expense: $1.3 billion
- 2015 research & development expense: $1.4 billion
- 2016 research & development expense: $1.4 billion
- 2017 research & development expense: $2.2 billion
Abbott Laboratories’ investment in research & development show that the company is willing to play the long game, building out its product pipeline and improving its long-term business growth prospects.
Abbott also has a competitive advantage that comes from its laser-sharp focus on shareholder value. In many ways, this starts at the top of the business via the leadership of Miles D. White. Mr. White, a Stanford-educated mechanical engineer and businessman by training, is nearing his 20-year anniversary as Abbott’s Chief Executive Officer.
As a large, diversified healthcare business, Abbott Laboratories is extraordinarily recession-resistant. The company actually managed to increase its adjusted earnings-per-share during each year of the 2007-2009 financial crisis.
- 2007 earnings-per-share of $2.84
- 2008 earnings-per-share of $3.03
- 2009 earnings-per-share of $3.72
- 2010 earnings-per-share of $4.17
Abbott Laboratories remarkably managed to grow its earnings-per-share during the global financial crisis – one of the most economically difficult time periods on record. At the same time, the company’s share count increased. Abbott Laboratories didn’t use share repurchases to grow earnings-per-share, they were simply more profitable during a tumultuous time. We expect this recession-resistant Dividend Aristocrat to perform similarly well during future downturns in the business environment.
From a dividend perspective, Abbott Laboratories’ dividend also appears very safe. You can watch our detailed analysis on Abbott Labs’ dividend safety below:
Valuation & Expected Total Returns
When Abbott Laboratories reported third-quarter earnings in October, the company narrowed its full-year adjusted earnings-per-share guidance to $2.87-$2.89. This performance forecast gives investors a benchmark by which to assess the company’s current valuation.
Abbott Laboratories is currently trading at $68/share. Using this price combined with the midpoint of the company’s guidance ($2.88) gives a price-to-earnings ratio of 23.6.
Abbott Laboratories’ has traded with an average price-to-earnings ratio of 19 over the past five years. The current valuation is noticeably higher than its long-term average. If shares revert to our fair value estimate of 19, this would reduce total returns by 4.2% per year. While right now may not be the best time to purchase shares of this high-quality business, total return may still be satisfactory particularly when adjusted for the low-risk nature of Abbott’s business model.
The other major component of Abbott Laboratories’ future total returns will be the company’s earnings-per-share growth. As we’ve seen, the company has a proven ability to grow earnings in the high-single-digits each year. We expect that this growth is likely to continue and investors can reasonably expect 6.5% in annual adjusted earnings-per-share growth moving forward.
Lastly, Abbott’s total returns will receive a boost from the company’s dividend payments. After increasing its dividend 14.3% in mid December, Abbott Laboratories now pays a quarterly dividend of $0.32 which yields 1.9% on the company’s current stock price of $68.
In sum, Abbott Laboratories’ expected total returns will be composed of:
- 6.5% earnings-per-share growth
- 1.9% dividend yield
- 4.3% multiple reversion
Total expected total annual returns are forecast at 4.1% through 2024.
Abbott Laboratories has many of the characteristics of an appealing dividend investment. It has a recession-resistant business model that allows it to continue growing earnings-per-share through various economic environments. It also has a long history of steadily increasing dividend payments.
While the company’s current valuation exceeds its long-term average, Abbott Laboratories remains a strong hold and we recommend that investors buy this high-quality stock on any notable dips.